SPY338.48-7.30 -2.11%
DIA276.09-7.25 -2.56%
IXIC11,320.30-227.98 -1.97%

Volition Veterinary Diagnostics Development LLC to Present Product Data Regarding its Nu.Q™ Vet Cancer Screening Test at the 2020 VCS Virtual Annual Conference

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans

· 10/12/2020 08:04

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will present two abstracts relating to its first product, the Nu.Q™ Vet Cancer Screening Test, at the 2020 Veterinary Cancer Society (VCS) Virtual Annual Conference, which takes place from Thursday, October 15 through Saturday, October 17.

The first abstract "Characterizing Circulating Nucleosomes in the Plasma of Dogs with Lymphoma," will be presented on Friday, October 16 at 1:30 p.m. Eastern Time.

The second abstract, "Characterizing Circulating Nucleosomes in the Plasma of Dogs with Hemangiosarcoma," will be presented on Saturday, October 17 at 11:15 a.m. Eastern Time.

Volition will release further details regarding these abstracts on Friday, October 16.

Volition is proud to sponsor the 2020 VCS Virtual Annual Conference and will be providing more information about the veterinary applications of its Nucleosomics™ technology for early detection of cancer and other diseases from a virtual exhibition booth at the event. 

To register for this conference click here.

The abstracts will be posted to the Volition website on Monday October 19.